SCHEMBL7678095

SCHEMBL7678095

CCCCC1C(=O)Oc2cc(C(=O)c3ccccc3)n(C)c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.40
LMNA P02545 4/20 0.40
MAPT P10636 4/20 0.40
CYP3A4 P08684 2/20 0.40
HPGD P15428 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
TP53 P04637 2/20 0.40
MAPK1 P28482 1/20 0.40
PTGS1 P23219 1/20 0.40
RAB9A P51151 1/20 0.40
NAPRT Q6XQN6 1/20 0.40
CNR2 P34972 2/20 0.37
NPSR1 Q6W5P4 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GLA P06280 2/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7680776 0.93 ALDH1A1 (0.39) ALDH1A1LMNAMAPTHPGDMAPK1
SCHEMBL7682039 0.79 MEN1 (0.37) MAPTTP53CNR2POLBMEN1
SCHEMBL7684736 0.78 ATM (0.34) ALDH1A1LMNAMAPTHPGDTP53
SCHEMBL7676758 0.73 NPSR1 (0.40) ALDH1A1LMNACYP1A2CYP2C9CYP2C19
SCHEMBL7675490 0.72 HPGD (0.37) ALDH1A1LMNAMAPTHPGDRAB9A
SCHEMBL7678670 0.71 CXCL8 (0.36) ALDH1A1LMNAMAPTCYP3A4HPGD
SCHEMBL7678067 0.70 CXCL8 (0.41) ALDH1A1LMNAMAPTHPGDCYP1A2
SCHEMBL7678489 0.69 HTT (0.46) ALDH1A1LMNAMAPTCYP1A2CYP2C9
SCHEMBL7678781 0.68 HTT (0.46) ALDH1A1LMNAMAPTHPGDCYP2C9
SCHEMBL4592036 0.67 KMT2A (0.46) ALDH1A1LMNAMAPTCYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A ALDH1A1 208/4885LMNA 2230/4885MAPT 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.